Inclusion Criteria:
- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic,
recurrent, and/or unresectable) with measurable disease or metastatic disease
documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions
on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For
Part 2B participants with HCC, intermediate disease is allowed.
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Must have received, and then progressed, relapsed, or been intolerant to, at least 1
standard treatment regimen in the advanced or metastatic setting according to tumor
type, if such a therapy exists
- Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are
permitted for some participants
- Willing and able to comply with all study procedures
Exclusion Criteria:
- Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the
only site of disease or active brain metastases will be excluded
- Other active malignancy requiring concurrent intervention
- Prior organ allograft
- Active, known, or suspected autoimmune disease
Other protocol-defined inclusion/exclusion criteria apply
Active, Not Recruiting
